linjc16/ctgov huggingface dataset:
Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus

Study Overview
=================
Brief Summary
-----------------
Lichen planus (LP) is a common chronic inflammatory mucocutaneous disease with an immunologic etiology ,which has number of different clinical forms. Alternative natural or herbal origine drugs with antioxidant and anti-inflammatory properties have been used individually or in combination with systemic corticosteroids in order to decrease adverse drug reactions. This study was conducted to evaluate the effect of quercetin on treatment of erosive -atrophic lesions of oral lichen planus (OLP).

Conditions
-----------------
Atrophic Oral Lichen Planus, Erosive Oral Lichen Planus

Intervention / Treatment
-----------------
* Drug: placebo
* Drug: Quercetin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmation of clinical diagnosis of Atrophic and erosive lichen planus by histological examination two weeks wash out periods after the last treatment having the experience of atrophic and erosive lesion greater than 1 cm having the experience of pain and burning greater than 3.5 in VAS Score Exclusion Criteria: confirmation of dysplasia and malignancy in histologic examination confirmation of lichenoid reaction in histologic examination pregnancy and breast feeding using fluorokinolon and cyclosporin which interact with quercetin

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: quercetin<br>quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action | Drug: Quercetin<br>* The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth<br>|
| Placebo Comparator: placebo<br>placebo capsul is produced with lactose for using in placebo/ control group. | Drug: placebo<br>* The patient is directed to use placebo capsule two times a day, ,until the one mouth<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the effects of this Drug on OLP measured with VAS scale for pain and evaluation of intensity of lesions. | In the present work the Analogical Visual Scale is used TO evaluate pain,and we also record the intensity of lesions weekly and any side effect of this Drug | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lichen planus, quercetin
Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker

Study Overview
=================
Brief Summary
-----------------
This project investigates circulating tumor DNA (ctDNA) in patients with suspected ovarian malignancy. We hypothesize that measurement of ctDNA in women with suspected ovarian cancer can improve the diagnostic efficiency for preoperative differentiation between benign and malignant masses. Specifically, we hope to determine the diagnostic efficiency of ctDNA alone and ctDNA in combination with imaging modalities (ultrasonography, MRI, PET-CT) and CA 125 for preoperative differentiation between benign and malignant adnexal masses. Based on this, we hope to develop an improved diagnostic algorithm. The mutational profile and relation to tumour type, stage, treatment response and prognosis will be explored. Analyses of blood and tissue samples will be used to examine the disease development and biology. Blood samples, tumour tissue and data on imaging modalities as well as CA 125 will be collected prospectively in consecutive women referred to Aarhus University Hospital.

Official Title
-----------------
Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker

Conditions
-----------------
Ovarian Neoplasms, Ovary Cancer, Ovarian Cysts

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected ovarian neoplasm Informed consent Exclusion Criteria: Inability to give informed consent Previous ovarian cancer diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic efficiency (reference: histopathological diagnosis) | Sensitivity, Specificity, Area under the receiver operation characteristic curve, positive and negative predictive values. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic efficiency of ctDNA combined with imaging (ultrasonography, MRI, PET-CT, CT, etc.) and CA 125 for differentiation of benign and malignant adnexal masses. | Area under the receiver operation characteristic curve, sensitivity, specificity, positive and negative predictive values. | 6 months | 
| Disease stage | FIGO stage | 6 months | 
| Treatment response | Response to treatment | 2 years | 
| Survival | Survival rate | 5 years | 
| Tumour Biology | Mutational profile assessed by Whole Exome Sequencing. | 6 months |
Fitostimoline Vaginal Pessaries in Women With Hysterectomy. Randomized, Perspective, Monoscentric Study.

Study Overview
=================
Brief Summary
-----------------
Clinical evaluation of Fitostimoline vaginal pessaries in the treatment of hysterectomy. An observational, randomized, perspective study performed on 60 women where 30 women are treated with fitostimoline pessaries and 30 women are treated with the standard of care.

Official Title
-----------------
Clinical Verification of the Activity and Tolerability of Fitostimoline Vaginal Pessaries in Women With Hysterectomy. Randomized, Perspective, Monoscentric Study.

Conditions
-----------------
Vaginal Bleeding

Intervention / Treatment
-----------------
* Drug: fitostimoline vaginal pessaries
* Other: standard of care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient aged between 35 and 80 years patient undergoing hysterectomy Willingness to understand the procedures and aims of the study Exclusion Criteria: Anamnestic or clinical data of metabolic or endocrine diseases (such as uncontrolled diabetes mellitus) or any other local and / or systemic pathology potentially able to interfere with the study parameters; Concomitant treatment with antibiotics / antiseptics, NSAIDs, analgesics (excl. Paracetamol) Non-therapeutic use of psychoactive substances; Abuse of drugs and / or alcohol / smoking; Neurological disorders or psychiatric conditions potentially capable of affecting the validity of the consent and / or compromising the patient's adherence to the study procedures; Known allergy, hypersensitivity or intolerance to the constituents of the preparations under study; Any condition, medical or otherwise, that could significantly reduce the possibility of obtaining reliable data, achieving the objectives of the study, perfecting its completion; Presumption of poor reliability or collaboration; Treatment with any preparation in the last 30 days prior to the start of the study; Patients already enrolled in this study; Center staff directly involved in the study and close relatives

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| fitostimoline vaginal pessaries<br> | Drug: fitostimoline vaginal pessaries<br>* vaginal pessaries<br>Other: standard of care<br>* standard of care<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TSS | total symptom score (TSS) on a scale from 0 to 10 from worst to best | 60 days |
INCIDENCE OF Delirium After Cardiac SURGERY Surgery

Study Overview
=================
Brief Summary
-----------------
Delirium is a common problem that occurs after cardiac surgery. The incidence of delirium after cardiac surgery is estimated to be 26-52%, with a significant percentage being hypoactive delirium1-4.Postoperative delirium has been associated with higher hospital costs, longer lengths of hospital stay, increased likelihood of institutionalization, increased risk for dementia, and increased morbidity and mortality.5-7 . The overall purpose of this study was to determine the incidence and perioperative factors that predispose to cause delirium in postoperative cardiac surgery patients in our ICU

Official Title
-----------------
Incidence And Predictors of Delirium After Cardiac Surgery; A Prospective Observational Cohort Study From a Single Tertiary Referral Centre

Conditions
-----------------
Delirium

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years old and older of both sexes Patients who signed an informed consent Patients scheduled for cardiac surgery with extracorporeal circulation (coronary-artery bypass grafting (CABG), cardiac valve replacement (CVR), combined CABG + CVR, excision of cardiac myxoma) Exclusion Criteria: Patients who refused to participate before or after operation; Patients in poor general condition; Patients with preoperative dementia, delirium or illiterate, psychiatric or mental disorder (epilepsy, schizophrenia, depression); Patients who died intraoperatively or within the first 6 hours after the procedure.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Without delirium<br> | |
| With delirium<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence and perioperative factors that predispose to cause delirium in postoperative cardiac surgery patients in our ICU | Incidence and perioperative risk factors that may predispose to delirium after cardiac surgery in our settings | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU stay and mechanical ventilation time | whetherICU stay in days and mechanical ventilation time in number of hours is affected by delirium | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
delirium;post-cardiac surgery;adults
The Incidence and Progression of Myopia: Cohort Study

Study Overview
=================
Brief Summary
-----------------
A cohort study on incidence and progression of myopia in a group of medical students

Detailed Description
-----------------
A prospective cohort study to investigate the refractive error development, progression and their risk factors in young adult population comprises a group of medical students in China for two years

Official Title
-----------------
A Cohort Study on Incidence and Progression of Myopia in a Group of Medical Students

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Other: Observation study only, no specific intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteer subject, , willing to follow the protocol and able to read, comprehend and sign the informed consent form, Age between 17 and 23 years Exclusion Criteria: Vulnerability of the subject, Participation in another study which might have an influence on vision or interfere with study assessments, Aphakic or pseudophakic (intraocular lens) Participants who are wearing ortho-K lenses, or undergone any kind of myopia control treatments or undergone refractive surgery. Any current or evolving pathology manifested in the eye or the appendages which might have an influence on vision, or interfere with study assessments (e.g. AMD, glaucoma…), Any previous ocular surgery which might have an influence on vision or interfere with study assessments (e.g. iridectomy, refractive surgery…), Any untreated and/or uncontrolled systemic condition which might have an influence on vision, or interfere with study assessments (e.g. uncontrolled diabetes, uncontrolled high blood pressure…), Any medical treatment or medication which might have an influence on vision or interfere with study assessments (e.g. antidepressants, drugs with atropinic effects…),

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 23 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Observation study only, no specific intervention|Observation study only, no specific intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| refraction | The participants will be measured for their refractive error by optometrist, and observe the rate of progression of myopia | Change from baseline for two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myopia
An Open-label Trial to Evaluate the Safety of an Essential Oil Infused Perineal Towel

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety (absence of skin irritation) of a feminine hygiene product for perineal hygiene prior to undertaking a clinical effectiveness trial. The feminine hygiene towel or wipe is an anti-bacterial Natural Health Product solution.

Detailed Description
-----------------
The design of the trial will be open-label and uncontrolled.

Official Title
-----------------
An Open-label Trial to Evaluate the Safety of an Essential Oil Infused Perineal Towel - WIPEAWAY

Conditions
-----------------
Urinary Tract Infections

Intervention / Treatment
-----------------
* Drug: Essential oils infused Perineal Hygiene wipe


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged ≥18 years willing to use the perineal towels for an entire month Exclusion Criteria: Pregnancy or within 12 months post-partum Current vulvo-vaginitis Known allergies to tea-tree oil

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Essential oils infused Perineal Hygiene wipe | Drug: Essential oils infused Perineal Hygiene wipe<br>* Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants without any adverse events as a measure of safety | Number of participants without any adverse events | 45 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ease of use of the perineal hygiene wipe by the participants on a daily basis | Ease of use of the perineal hygiene wipe by the participants on a daily basis | 30 Days | 
| Self-reported comfort score on a scale of 1 to 10 | Self-reported comfort score on a scale of 1 to 10 | 30 Days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Perineal hygiene, Hygiene wipes, Hygiene Towels, Safety, Essential oils, Natural Health Product
Ultrasound Evaluation of the Rotator Cable and Associated Structures.

Study Overview
=================
Brief Summary
-----------------
This study will use healthy volunteers and patients with shoulder problems (pain or impaired movement). Ultrasound will be used to image and document the appearance of both normal and abnormal shoulder structures.

Detailed Description
-----------------
The purpose of this study is to document normal and abnormal appearances of various shoulder structures (rotator cable and rotator cuff). This study will recruit healthy volunteers and patients who have been referred to Radiology for a symptomatic shoulder (a shoulder that is causing the patient pain, or is limited in its ability to move.) Both groups will undergo ultrasound imaging of the shoulder.

Official Title
-----------------
Ultrasound Evaluation of the Rotator Cable and Associated Structures.

Conditions
-----------------
Shoulder Pain

Intervention / Treatment
-----------------
* Other: ultrasound of painful shoulder
* Other: ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with shoulder pain referred to radiology for ultrasound of shoulder Exclusion Criteria: Patients less than 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Patients with shoulder pain who were clinically referred to Ultrasound for evaluation | Other: ultrasound of painful shoulder<br>* Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.<br>|
| Active Comparator: 2<br>healthy volunteers who do not have shoulder pain | Other: ultrasound<br>* Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine if Ultrasound can identify the rotator cable and the associated structures. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ultrasound, rotator cuff
A Controlled Pregabalin Trial In Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of pregabalin compared with placebo for the relief of pain associated with fibromyalgia and improvement of function of patients with fibromyalgia

Official Title
-----------------
A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Drug: pregabalin
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites. Patients must have a score of >40 mm on the Visual Analog Scale Exclusion Criteria: Patients with any widespread inflammatory musculoskeletal disorders, widespread rheumatic diseases other than fibromyalgia, active infections, or untreated endocrine disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: pregabalin|nan|
|Drug: placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the efficacy of pregabalin for pain relief by comparing the mean pain score between treatment groups and placebo. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the efficacy of pregabalin for improvement in sleep, fatigue, health-related quality of life, functioning and mood disturbance associated with fibromyalgia. To evaluate safety and tolerability. |  |  |